TScan Therapeutics, Inc. (TCRX)
TCRX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How TCRX actually reacts to news — the realized, point-in-time move the market made, measured across 213 labeled events over the last three years with zero look-ahead.
TCRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 213 |
| 30-min | 0.00% | 45% | 213 |
| 60-min | 0.00% | 45% | 213 |
| to close | 0.00% | 49% | 209 |
| Middle 50% of TCRX reactions | -1.58% to +1.42% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 213 |
Half of all TScan Therapeutics, Inc. news events land between -1.58% and +1.42% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TCRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 19 | -1.65% | 37% | -4.27% |
| Rating reiterations | 61 | -0.52% | 43% | -0.26% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how TCRX ranks against every other measured name →
That’s how TCRX usually reacts — get an email when it moves on news →Email me when TCRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TCRX's baseline. Nothing else.
Recent TCRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K TScan Therapeutics, Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -3.70% | -11.61% | |
| Form PRE 14A TScan Therapeutics, Inc. For: Nov 20 | SEC filing · Form PRE | SEC EDGAR | -3.70% | -11.61% | |
| Form 8-K TScan Therapeutics, Inc. For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -0.47% | |
| Form 8-K TScan Therapeutics, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -1.17% | |
| Form 8-K TScan Therapeutics, Inc. For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -9.98% | -30.71% | |
| TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors | Press release | GlobeNewswire | -9.98% | -30.71% | |
| Form 8-K TScan Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +5.51% | -2.60% | |
| Form 10-Q TScan Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.92% | -2.28% | |
| Form 8-K TScan Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -3.92% | -2.28% | |
| TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.92% | -2.28% | |
| TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies | Press release | GlobeNewswire | +1.75% | -4.31% | |
| TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | Press release | GlobeNewswire | -0.26% | -5.52% | |
| Form 8-K TScan Therapeutics, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | -1.28% | -7.23% | |
| TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation | Press release | GlobeNewswire | -1.28% | -7.23% | |
| Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies | Press release | Business Wire | -2.00% | -2.80% | |
| Form 8-K TScan Therapeutics, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | +1.91% | |
| Form 10-Q TScan Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.94% | +5.04% | |
| Form 8-K TScan Therapeutics, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +2.94% | +5.04% | |
| TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +2.94% | +5.04% | |
| TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting | Press release | GlobeNewswire | -4.58% | -3.82% | |
| Form ARS TScan Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.23% | +6.25% | |
| Form DEF 14A TScan Therapeutics, Inc. For: May 20 | SEC filing · Form DEF | SEC EDGAR | +2.23% | +6.25% | |
| TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -3.91% | -7.83% | |
| Form PRE 14A TScan Therapeutics, Inc. For: May 20 | SEC filing · Form PRE | SEC EDGAR | -3.91% | -7.83% | |
| Form 8-K TScan Therapeutics, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +2.00% | +1.00% | |
| Form 10-K TScan Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.91% | +2.86% | |
| Form 8-K TScan Therapeutics, Inc. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | +2.86% | |
| Form S-8 TScan Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.91% | +2.86% | |
| TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.91% | +2.86% | |
| TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 | Press release | GlobeNewswire | -3.48% | -3.48% | |
| TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +0.91% | +0.91% | |
| Form 8-K TScan Therapeutics, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -3.31% | |
| TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | Press release | GlobeNewswire | +0.92% | -8.26% | |
| TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities | Press release | GlobeNewswire | -1.44% | +4.81% | |
| Form 8-K TScan Therapeutics, Inc. For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | -5.88% | -6.72% | |
| Form 10-Q TScan Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.01% | -2.46% | |
| Form 8-K TScan Therapeutics, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -2.46% | |
| TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.01% | -2.46% | |
| TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference | Press release | GlobeNewswire | +0.00% | +1.34% | |
| Form 8-K TScan Therapeutics, Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -9.46% | -16.22% | |
| TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 | Press release | GlobeNewswire | -9.46% | -16.22% | |
| TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 | Press release | GlobeNewswire | +0.58% | -7.51% | |
| Form 8-K TScan Therapeutics, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | -3.16% | |
| TScan Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +8.09% | |
| Form 8-K TScan Therapeutics, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.19% | |
| Form 10-Q TScan Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.62% | — | |
| Form 8-K TScan Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.62% | — | |
| TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.62% | — | |
| Form 8-K TScan Therapeutics, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | +0.69% | |
| TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.69% | +0.69% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TCRX section they belong to.
Where else TCRX is measured.
TCRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TScan Therapeutics, Inc.'s median reaction calculated?
Every labeled TCRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 213 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of TCRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TCRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.